Company Filing History:
1 out of 1 
1 out of 1 
1 out of 10 Years Active: 2025
Title: Bing Liu: Innovator in Multi-Target Kinase Inhibitors
Introduction
Bing Liu is a prominent inventor based in Guangdong, China, recognized for his contributions in the field of pharmaceuticals, specifically relating to multi-target kinase inhibitors. His innovative work focuses on developing compounds that effectively treat a range of cancers and other diseases associated with abnormal signal transduction pathways.
Latest Patents
Bing Liu holds a notable patent for a "Multi-target kinase inhibitor, pharmaceutical composition, and preparation method for multi-target kinase inhibitor and use thereof." This patent outlines a multi-target kinase inhibitor characterized by a specific formula, where R is selected from multiple predefined formulas. The invention provides a pharmaceutical composition where the active ingredient, the multi-target kinase inhibitor, constitutes about 1-50 wt % of the total composition. This compound has proven effective in inhibiting the enzymatic activities of RET, VEGFR3, and PDGFRA, making it a potential treatment for various cancers, including those of the breast, respiratory tract, brain, reproductive organs, and more, along with lymphomas, sarcomas, and leukemias.
Career Highlights
Throughout his career, Bing Liu has been associated with reputable companies in the biotechnology and biomedical sectors. He has worked at Guangzhou Liushun Biotechnology Co., Ltd. and Beijing Beikehuaxia Biomedical Technology Co., Ltd. These affiliations have provided him with the platform to advance his research and development in pharmaceuticals.
Collaborations
In his professional journey, Bing Liu has collaborated with notable colleagues, including Jingsi Dai and Yan Wang. Together, they have contributed to the advancement of biotechnology and enriched the field with innovative practices and discoveries.
Conclusion
Bing Liu's work represents a critical advancement in the understanding and treatment of cancers through multi-target kinase inhibitors. His patented invention and collaborations underscore the importance of innovation in the pharmaceutical industry, paving the way for future research and therapeutic developments.